• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population
Int J Biol Macromol. 2023 Feb 7:123586. doi: 10.1016/j.ijbiomac.2023.123586. Online ahead of print.ABSTRACTA high level of lipoprotein (a) in the plasma has been associated with a variety of cardiovascular diseases and is considered to be an independent predictor of some other diseases. Based on recent studies, the concentration levels of Lp(a) in the Chinese population exhibit a distinctive variation from other populations. In the Chinese population, a high level of Lp(a) indicates a higher incidence of revascularization, platelet aggregation, and thrombogenicity following PCI. Increased risk of atherosclerotic cardiovasc...
Source: International Journal of Biological Macromolecules - February 9, 2023 Category: Biochemistry Authors: Zubair Hussain Hongcai Liu Junaid Iqbal Hou-De Zhou Source Type: research

A Randomized Controlled Trial Comparing Apixaban to the Vitamin K-antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 study
Conclusions: In this randomized trial comparing apixaban and VKA in patients with AF on hemodialysis with long follow-up, no differences were observed in safety or efficacy outcomes. Even on oral anticoagulation, patients with AF on hemodialysis remain at high risk of cardiovascular events. Larger randomized trials are needed to determine the optimal anticoagulation regimen for patients with AF on hemodialysis. Clinical Trial Registration: EudraCT No. 2015-005503-84, NCT02933697.PMID:36335915 | DOI:10.1161/CIRCULATIONAHA.122.062779
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Holger Reinecke Christiane Engelbertz Rupert Bauersachs G ünter Breithardt Hans-Herbert Echterhoff Joachim Ger β Karl Georg Haeusler Bernd Hewing Joachim Hoyer Sabine Juergensmeyer Thomas Klingenheben Guido Knapp Lars Christian Rump Hans Schmidt-Guertle Source Type: research

Long-Term Effectiveness of Cilostazol in Patients with Hemodialysis with Peripheral Artery Disease
CONCLUSION: Continuous treatment of cilostazol in patients with HD with PAD significantly decreases the risk of ED visits, hemorrhagic stroke, and cardiovascular events and improves ED visit-free and cardiovascular event-free rates during long-term follow-up.PMID:36216573 | DOI:10.5551/jat.63404
Source: Journal of Atherosclerosis and Thrombosis - October 10, 2022 Category: Cardiology Authors: Chung-Kuan Wu Chia-Hsun Lin Noi Yar Zih-Kai Kao Ya-Bei Yang Yun-Yi Chen Source Type: research

Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse
Front Biosci (Schol Ed). 2022 Jul 21;14(3):21. doi: 10.31083/j.fbs1403021.ABSTRACTThe most frequent arrhythmia treated is atrial fibrillation (AF), which necessitates the use of oral anticoagulants (OACs) to reduce the risk of thromboembolism and stroke. Patients with chronic kidney disease are more likely to develop AF, with a 10% frequency among those on chronic dialysis. Warfarin is the most widely prescribed OAC for individuals with end-stage kidney disease (ESKD). On the other hand, direct OACs (DOACs) are generally safer than warfarin, with fewer fatal bleeding events and a fixed dose that does not require close inte...
Source: Frontiers in Bioscience - Scholar - September 22, 2022 Category: Biomedical Science Authors: Nikolaos Ktenopoulos Marios Sagris Panagiotis Theofilis Sophia Lionaki Loukianos S Rallidis Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11